All News

yellow box among blue

If We Can’t Prevent RA, Can We at Least Prevent Difficult-to-Treat RA?

d Aurelie Najm, MD, PhD

Two new studies presented this year tackle a key question: can our initial treatment choices influence who ends up in the difficult-to-treat category?

Read Article
time

The Long View of Diagnostic Delay in Axial Spondyloarthritis

d Antoni Chan, MD, PhD

Axial spondyloarthritis (axSpA) remains a diagnostic challenge, particularly in its early stages before structural sacroiliitis is visible on imaging.

Read Article
Conv3.jpg

ACR 2025 – Day 2 Report

d Jack Cush, MD

Here are 3 abstracts that caught my eye on Day 2 at ACR25. Notably these have takeaway messages that should support your current practices.

Read Article
ACR Best

ACR25 Best Abstracts - Day 2

d Jack Cush, MD

After a full day at the Chicago Convention center the RheumNow faculty have posted some of their favorite reports included these that they labeled as being the "best' of day 2.

Read Article
CAR-T

Are we putting the CAR-T before the horse?

d Richard Conway, MBBChBAO, PhD

CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure.

Read Article
#ACR25 Please find my video interview with Dr Kate Rochlin on a novel Bi-specific T-cell engager (BiTE) in development which binds to pan-gamma delta T-cell instead of CD3 to minimise risk of cytokine release syndrome side effect. Abstr#1535 @RheumNow https://t.co/MOmUm41cyA https://t.co/TgIUGgWGw5

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
🎥 LIVE from #ACR25 Join us daily at 5 PM CST for RheumNow’s ACR Recap Live - Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways. Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live. Save the time. Be part of https://t.co/ZgZM14L6ta
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Please find my video interview with Prof Edward Vital @edvital on their work on International Consensus of Glucocorticoid Tapering Guideline in #SLE #lupus Abstr#1526 @RheumNow https://t.co/MnQdcdASkG https://t.co/b7GMcnFU2m

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Management of cardiac and joint sarcoidosis. Use of TNFi in treatment refractory cases. Alana Nevares-Berrios @RheumNow #ACR25 https://t.co/hXOfkgQHP9

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#ACR25 Please find my video and take on Abstr#0646. Promising new Bi-specific T-cell engager (BiTE) other than Blinatumomab in #SLE @RheumNow https://t.co/5JrLG41nsD https://t.co/KeY6AkHUNK

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR25 Please find my video and take on Abstr#0803. Should we use Belimumab before- or after a trial of concentional immunosuppressant in #SLE? @RheumNow https://t.co/ExIvrdJXw5 https://t.co/AVb5ohWwXZ

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
SLGT-2 and GLP-1 in RA: More than Weight Loss https://t.co/SRKMHNlHZo Future of rheumatology is bright , Shreya Sakthivel discussed her work on TriNetX database , looking specifically for effect of SLGT-2. GLP-1 on RA flare incidence. @RheumKay @RheumNow #acr25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

GLP-1 in Knee Osteoarthritis https://t.co/SxyVEAK1CZ @bella_mehta Discusses role of GLP1 in OA and possible mechanisms of effectiveness ? weight reduction ? or doses it have anti-inflammatory -anti-fibrotic role ? @RheumNow #ACR25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

Progressive BiTE in SLE 2 https://t.co/ykMQmSAdlb More on BiTES in SLE by the one and only @Yuz6Yusof Bi specific Tcell engager ( CD3-CD19). @RheumNow #ACR25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

New Paradigms in RA Treatment https://t.co/CqpI2znglE @jeffsparks Highlights new trials in RA 1-Neuro immune modulation ( Vagal nerve stimulation). 2-Targeting pathogenic T cells 3-T reg CAR-T ( Peace maker). @RheumNow #ACR25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

Day 2 Recap: ACR Convergence 2025 Highlights https://t.co/b8XvrEsoLW Such a great time to be a rheumatologist. Fake rheumatology sounds like a great topic! Daily challenges and unusual presentations. @DrMiniDey @synovialjoints @drdavidliew @RheumNow #ACR25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

#ACR25 Abstr#0855 Five extra patients were added to complete IMPACT Open Label Phase 2 trial of add-on Certolizumab in APS women + LAC+ve. Results stood: primary endpoint was met (adverse pregnancy outcome=19.6%; lower than 20% expected). Significant enough to adopt @RheumNow https://t.co/zhFVGYXiaU

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

#ACR25 Day 1 RECAP Big takeaways, standout moments, and what set the tone for this year’s conference. We break down the key insights, early trends, and conversations shaping Day 1. https://t.co/js5FVBvUfk https://t.co/smh1AyPhfa

Links:

Dr. John Cush RheumNow ( View Tweet)
Stress Raises the Risk of Psoriasis New longitudinal research reveals that severe stress caused by changes in family structure like divorce or separation experienced during the first year of life may triple the risk of developing psoriasis later in life. https://t.co/TSXoQKjRPN
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×